Royalty Pharma 2016 Investor Presentation

Royalty Pharma presents a diversified long-acting bronchodilator royalty portfolio generating strong cash returns, with 32% quarterly compounded growth in royalty revenue over the past 10 quarters. The company holds royalty rights to GSK's RELVAR/BREO and ANORO ELLIPTA products, supported by a solid balance sheet with $150M cash and disciplined capital allocation returning over $210M to investors since 2015. The portfolio is anchored by significant market opportunities in the growing COPD and asthma markets, with royalties extending into the late 2020s.